Circassia Ltd, an Oxford, UK-based biopharmaceutical company focused on allergy, announced that it has completed a £15m (approximately $25m) in a significantly oversubscribed 3rd funding round.
The round was led by Imperial Innovations with participation from existing shareholders including Invesco Perpetual and Lansdowne Partners.
The investment follows recently announced positive phase II results with allergy T-cell vaccines based on its proprietary ToleroMune(R) technology.
The financing will support the acceleration of the programme into late-stage development and advance the clinical development of Circassia’s broader portfolio of novel allergy vaccines.
FinSMEs
11/12/2009